179 related articles for article (PubMed ID: 22329596)
21. IncobotulinumtoxinA (Xeomin®) injected for blepharospasm or cervical dystonia according to patient needs is well tolerated.
Evidente VG; Truong D; Jankovic J; Comella CL; Grafe S; Hanschmann A
J Neurol Sci; 2014 Nov; 346(1-2):116-20. PubMed ID: 25186131
[TBL] [Abstract][Full Text] [Related]
22. Satisfaction with botulinum toxin treatment: a cross-sectional survey of patients with cervical dystonia.
Sethi KD; Rodriguez R; Olayinka B
J Med Econ; 2012; 15(3):419-23. PubMed ID: 22208596
[TBL] [Abstract][Full Text] [Related]
23. Comparison of treatment of tardive dystonia and idiopathic cervical dystonia with botulinum toxin type A.
Brashear A; Ambrosius WT; Eckert GJ; Siemers ER
Mov Disord; 1998 Jan; 13(1):158-61. PubMed ID: 9452343
[TBL] [Abstract][Full Text] [Related]
24. A prospective, randomized, double-blind study comparing the efficacy and safety of type a botulinum toxins botox and prosigne in the treatment of cervical dystonia.
Quagliato EM; Carelli EF; Viana MA
Clin Neuropharmacol; 2010; 33(1):22-6. PubMed ID: 19959960
[TBL] [Abstract][Full Text] [Related]
25. Spectral EMG Changes in Cervical Dystonia Patients and the Influence of Botulinum Toxin Treatment.
Nijmeijer SWR; de Bruijn E; Verhagen R; Forbes PA; Kamphuis DJ; Happee R; Tijssen MAJ; Koelman JHTM
Toxins (Basel); 2017 Aug; 9(9):. PubMed ID: 28832550
[TBL] [Abstract][Full Text] [Related]
26. Cost-utility analysis of botulinum toxin type A products for the treatment of cervical dystonia.
Kazerooni R; Broadhead C
Am J Health Syst Pharm; 2015 Feb; 72(4):301-7. PubMed ID: 25631837
[TBL] [Abstract][Full Text] [Related]
27. A mixed treatment comparison to compare the efficacy and safety of botulinum toxin treatments for cervical dystonia.
Han Y; Stevens AL; Dashtipour K; Hauser RA; Mari Z
J Neurol; 2016 Apr; 263(4):772-80. PubMed ID: 26914922
[TBL] [Abstract][Full Text] [Related]
28. Sensorimotor network in cervical dystonia and the effect of botulinum toxin treatment: a functional MRI study.
Opavský R; Hluštík P; Otruba P; Kaňovský P
J Neurol Sci; 2011 Jul; 306(1-2):71-5. PubMed ID: 21492880
[TBL] [Abstract][Full Text] [Related]
29. Comparison Between Dysport and Prosigne in the Treatment of Cervical Dystonia.
Barbosa PM; Rodrigues GR; de Oliveira DS; de Souza CP; Tumas V
Clin Neuropharmacol; 2015; 38(6):221-6. PubMed ID: 26536017
[TBL] [Abstract][Full Text] [Related]
30. Dysport and Botox at a ratio of 2.5:1 units in cervical dystonia: a double-blind, randomized study.
Yun JY; Kim JW; Kim HT; Chung SJ; Kim JM; Cho JW; Lee JY; Lee HN; You S; Oh E; Jeong H; Kim YE; Kim HJ; Lee WY; Jeon BS
Mov Disord; 2015 Feb; 30(2):206-13. PubMed ID: 25476727
[TBL] [Abstract][Full Text] [Related]
31. INTEREST IN CD2, a global patient-centred study of long-term cervical dystonia treatment with botulinum toxin.
Misra VP; Colosimo C; Charles D; Chung TM; Maisonobe P; Om S;
J Neurol; 2018 Feb; 265(2):402-409. PubMed ID: 29270685
[TBL] [Abstract][Full Text] [Related]
32. Clinical experience of dose conversion ratios between 2 botulinum toxin products in the treatment of cervical dystonia.
Rystedt A; Nyholm D; Naver H
Clin Neuropharmacol; 2012; 35(6):278-82. PubMed ID: 23123690
[TBL] [Abstract][Full Text] [Related]
33. Efficacy and safety of a standardised 500 unit dose of Dysport (clostridium botulinum toxin type A haemaglutinin complex) in a heterogeneous cervical dystonia population: results of a prospective, multicentre, randomised, double-blind, placebo-controlled, parallel group study.
Wissel J; Kanovsky P; Ruzicka E; Bares M; Hortova H; Streitova H; Jech R; Roth J; Brenneis C; Müller J; Schnider P; Auff E; Richardson A; Poewe W
J Neurol; 2001 Dec; 248(12):1073-8. PubMed ID: 12013585
[TBL] [Abstract][Full Text] [Related]
34. Efficacy and safety of abobotulinumtoxinA liquid formulation in cervical dystonia: A randomized-controlled trial.
Poewe W; Burbaud P; Castelnovo G; Jost WH; Ceballos-Baumann AO; Banach M; Potulska-Chromik A; Ferreira JJ; Bihari K; Ehler E; Bares M; Dzyak LA; Belova AN; Pham E; Liu WJ; Picaut P
Mov Disord; 2016 Nov; 31(11):1649-1657. PubMed ID: 27653448
[TBL] [Abstract][Full Text] [Related]
35. [Botulinum toxin treatment of hip adductor spasticity in multiple sclerosis].
Wissel J; Entner T
Wien Klin Wochenschr; 2001; 113 Suppl 4():20-4. PubMed ID: 15506048
[TBL] [Abstract][Full Text] [Related]
36. The dystonia discomfort scale (DDS): a novel instrument to monitor the temporal profile of botulinum toxin therapy in cervical dystonia.
Dressler D; Kupsch A; Seitzinger A; Paus S
Eur J Neurol; 2014 Mar; 21(3):459-62. PubMed ID: 24433495
[TBL] [Abstract][Full Text] [Related]
37. Quantitative electromyography-guided botulinum toxin treatment of cervical dystonia.
Finsterer J; Fuchs I; Mamoli B
Clin Neuropharmacol; 1997 Feb; 20(1):42-8. PubMed ID: 9037572
[TBL] [Abstract][Full Text] [Related]
38. Quality of life improvements in patients with cervical dystonia following treatment with a liquid formulation of abobotulinumtoxinA (Dysport
Simonetta-Moreau M; Picaut P; Volteau M; Poewe W
Eur J Neurol; 2019 Jun; 26(6):943-e65. PubMed ID: 30168896
[TBL] [Abstract][Full Text] [Related]
39. Use of AbobotulinumtoxinA in Adults with Cervical Dystonia: A Systematic Literature Review.
Fasano A; Paramanandam V; Jog M
Toxins (Basel); 2020 Jul; 12(8):. PubMed ID: 32722133
[TBL] [Abstract][Full Text] [Related]
40. The Impact of the Course of Disease before Botulinum Toxin Therapy on the Course of Treatment and Long-Term Outcome in Cervical Dystonia.
Hefter H; Schomaecker I; Schomaecker M; Rosenthal D; Samadzadeh S
Toxins (Basel); 2021 Jul; 13(7):. PubMed ID: 34357965
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
